Abstract 6274: Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of myeloproliferative neoplasms (MPN)
Michelle Pusey(Incyte (United States)), Sunkyu Kim(Korea University), Kristy R. Stengel(Albert Einstein College of Medicine), Jacob Ellis(Vanderbilt University), Gaurang Trivedi(Incyte (United States)), Cynthia Timmers(Cancer Genetics (United States)), Susan Wee(Bristol-Myers Squibb (United States)), Nina Zolotarjova(Incyte (United States)), Jeff Jackson(Incyte (United States)), Scott W. Hiebert(Vanderbilt University), Hamza Celik(Incyte (United States)), Matt Stubbs(Incyte (United States)), Bob Collins(Incyte (United States)), Pat Feldman(Incyte (United States)), Monica Bomber(Vanderbilt University)
Cited by 2
Related Papers
The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F.
|Genes & Development|1992|592
Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
|The EMBO Journal|2008|265
Myocardial Infarction Activates CCR2+ Hematopoietic Stem and Progenitor Cells
|Cell stem cell|2015|217
<i>E2f1</i>, <i>E2f2</i>, and <i>E2f3</i> Control E2F Target Expression and Cellular Proliferation via a p53-Dependent Negative Feedback Loop
|Molecular and Cellular Biology|2007|110
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
|Molecular Case Studies|2019|88